{"id":179263,"date":"2021-02-16T01:33:43","date_gmt":"2021-02-15T22:33:43","guid":{"rendered":"https:\/\/en.buradabiliyorum.com\/covid-19-study-revives-heavily-disputed-vitamin-d-theory\/"},"modified":"2021-02-16T01:33:43","modified_gmt":"2021-02-15T22:33:43","slug":"covid-19-study-revives-heavily-disputed-vitamin-d-theory","status":"publish","type":"post","link":"https:\/\/buradabiliyorum.com\/en\/covid-19-study-revives-heavily-disputed-vitamin-d-theory\/","title":{"rendered":"#COVID-19 study revives heavily disputed vitamin D theory"},"content":{"rendered":"

“#COVID-19 study revives heavily disputed vitamin D theory<\/strong>”
\n<\/p>\n

\n

Doctors can\u2019t seem to decide on vitamin D.<\/p>\n

At the height of the global coronavirus outbreak, physicians had begun to note a correlation between vitamin-D deficiency and COVID-19 illness severity, with one study finding 80% of patients who ultimately succumbed to the disease were frequently also low on the nutrient, which we derive primarily from sunlight.<\/p>\n

However, these reports have been disputed by researchers who remain conservative in regard to supplementation, calling for further research before consumers are encouraged to add vitamin-D capsules to their diets.<\/p>\n

Vitamin-D deficiency has long been on the rise as humans spend less time working and being outdoors and more time toiling inside offices and online \u2014 and that\u2019s true now more than ever during the pandemic.<\/p>\n

But a new report by Spanish researchers at the Hospital del Mar in Barcelona has added evidence to the pro-D camp, particularly D3 or calcifediol, as a treatment for coronavirus patients. Their study of 930 COVID-19 patients found that those who received the supplement, rather than a placebo, saw a \u201creduced mortality of more than 60%,\u201d study authors wrote. These patients were additionally 80% less likely to require intensive care at the hospital. <\/p>\n

Just 36 of the 551 patients who took calcifediol died from the coronavirus. Meanwhile, the control group of 379 patients lost 57 to the disease. Furthermore, just 5% of the cohort taking D3 were admitted to the ICU.<\/p>\n

\u201cThis supports the conclusion of a prior pilot trial<\/a> in C\u00f3rdoba [Spain] in which calcifediol treatment lead to a reduction of more than 50% of ICU admission in hospitalized COVID-19 patients,\u201d according to the full report<\/a>.<\/p>\n

The findings were shared by the Social<\/a> Science<\/a> Research Network as pre-published material<\/a>, awaiting review from medical research peers. This hasn\u2019t stopped some policy leaders from praising the unchecked findings, such as British legislator David Davis, who called on<\/a> health officials in the UK to heed the study results.<\/p>\n

\u201cIts findings are incredibly clear,\u201d MP Davis said<\/a> on Sunday, in a tweet liked by 25,000 users on Twitter. \u201cAn 80% reduction in need for ICU and a 60% reduction in deaths, simply by giving a very cheap and very safe therapy.\u201d<\/p>\n

However, Yale researcher F. Perry Wilson has called the new report \u201csuper sus\u201d in a series of tweets<\/a> fired off on Sunday.<\/p>\n

\n
\n
\n
\n

Folks, we need to talk about this Vitamin D trial. I have no stake in this game<\/a> \u2013 take Vitamin D if you want but this pre-print is super sus. (THREAD)https:\/\/t.co\/QZNp8kOXsv<\/a><\/p>\n

\u2014 F. Perry Wilson, MD MSCE (@fperrywilson) February 14, 2021<\/a><\/p><\/blockquote>\n<\/div>\n<\/div>\n<\/figure>\n

\u201cFolks, we need to talk about this Vitamin D trial. I have no stake in this game \u2014 take Vitamin D if you want but this pre-print is super sus,\u201d he wrote.<\/p>\n

\u201cIf true, this would be one of (if not THE most) effective treatments for COVID. But there are problems. . .,\u201d suggested Wilson, pointing out that the type of \u201crandomized\u201d trial performed by doctors at Hospital del Mar was inconsistent with the statistical model used to produce the results. <\/p>\n

\u201cThis is super basic stuff \u2014 you don\u2019t call your study a randomized trial when it\u2019s a cluster randomized trial,\u201d he added. \u201cAnd peer-reviewers would 100% have asked them to go back and redo the stats.\u201d\n <\/p><\/div>\n